Motif Neurotech Gains FDA Clearance to Launch First-in-Human Trial of Implantable BCI for Depression
As reported on Business Wire, Motif Neurotech has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its first clinical study evaluating an implantable brain–computer interface (BCI)…